Topobexin

Overview

Topobexin is a TOP2B -selective inhibitor with IC 50 values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Topoisomerase

Product Information

• Catalog No.: HY-174374
• CAS No.: 3076446-44-8
• Molecular Formula: C29H35N3O4
• Molecular Weight: 489.61
• Purity: 99.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution
• Availability: In-stock

Source

Original product source